{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:39:45Z","timestamp":1789763985308,"version":"4.0.1"},"reference-count":87,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive, neurodegenerative disease caused by biallelic mutations in the survival motor neuron 1 (<jats:italic>SMN1<\/jats:italic>) gene. SMA is characterized by motor neuron degeneration, resulting in progressive muscle atrophy and weakness. Before the emergence of disease\u2010modifying therapies, children with the most severe form of SMA would never achieve the ability to sit independently. Only 8% survived beyond 20\u2009months of age without permanent ventilator support. One such therapy, onasemnogene abeparvovec, an adeno\u2010associated virus\u2013based gene replacement therapy, delivers functional human<jats:italic>SMN<\/jats:italic>through a one\u2010time intravenous infusion. In addition to substantially improving survival, onasemnogene abeparvovec was found to increase motor milestone attainment and reduce the need for respiratory or nutritional support in many patients. This expert opinion provides recommendations and practical considerations on the patient\u2010centered decisions to use onasemnogene abeparvovec. Recommendations include the need for patient\u2010centered multidisciplinary care and patient selection to identify those with underlying medical conditions or active infections to reduce risks. We also describe the importance of retesting patients with elevated anti\u2013adeno\u2010associated virus serotype 9 antibodies. Recommendations for prednisolone tapering and monitoring for potential adverse events, including hepatotoxicity and thrombotic microangiopathy, are described. The need for caregiver education on managing day\u2010to\u2010day care at time of treatment and patient\u2010 and family\u2010centered discussions on realistic expectations are also recommended. We detail the importance of following standard\u2010of\u2010care guidance and long\u2010term monitoring of all children with SMA who have received one or more disease\u2010modifying therapy using registries. We also highlight the need for presymptomatic or early symptomatic treatment of this disorder.<\/jats:p>","DOI":"10.1002\/mus.27363","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T10:46:51Z","timestamp":1625136411000},"page":"413-427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy"],"prefix":"10.1002","volume":"64","author":[{"given":"Elizabeth A.","family":"Kichula","sequence":"first","affiliation":[{"name":"Children's Hospital of Philadelphia Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Proud","sequence":"additional","affiliation":[{"name":"Children's Hospital of the King's Daughters Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[{"name":"School of Women's and Children's Health, UNSW Medicine University of New South Wales Sydney and Sydney Children's Hospital Network Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kwon","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health University of Wisconsin Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Saito","sequence":"additional","affiliation":[{"name":"Institute of Medical Genetics, Tokyo Women's Medical University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desguerre","sequence":"additional","affiliation":[{"name":"Necker\u2010Enfants Malades Hospital University of Paris, AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario University of Ottawa Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"e_1_2_25_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2670"},{"key":"e_1_2_25_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"e_1_2_25_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00125817-200201000-00004"},{"key":"e_1_2_25_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003"},{"key":"e_1_2_25_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/338627"},{"key":"e_1_2_25_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(94)00075-K"},{"key":"e_1_2_25_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(06)80015-5"},{"key":"e_1_2_25_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(99)80012-9"},{"key":"e_1_2_25_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91835-3"},{"key":"e_1_2_25_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"e_1_2_25_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-102319-103602"},{"key":"e_1_2_25_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"e_1_2_25_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.05.005"},{"key":"e_1_2_25_15_1","unstructured":"Zolgensma (onasemnogene abeparvovec\u2010xioi). Package insert. AveXis Inc 2021.https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/zolgensma.pdf. Accessed March 19 2021."},{"key":"e_1_2_25_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.06.007"},{"key":"e_1_2_25_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300994"},{"key":"e_1_2_25_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.13.7689-7695.2003"},{"key":"e_1_2_25_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3389"},{"key":"e_1_2_25_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(02)00023-0"},{"key":"e_1_2_25_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.009"},{"key":"e_1_2_25_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.112"},{"key":"e_1_2_25_23_1","unstructured":"Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X\u2010linked myotubular myopathy. Updated August 20 2020.https:\/\/www.audentestx.com\/press_release\/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy. Accessed October 11 2020."},{"key":"e_1_2_25_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1515"},{"key":"e_1_2_25_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5"},{"key":"e_1_2_25_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301514"},{"key":"e_1_2_25_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/104303401300042500"},{"key":"e_1_2_25_28_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190403"},{"key":"e_1_2_25_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_2_25_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_2_25_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1272"},{"key":"e_1_2_25_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27034"},{"key":"e_1_2_25_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073820928784"},{"key":"e_1_2_25_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2015.06.002"},{"key":"e_1_2_25_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0673-0"},{"key":"e_1_2_25_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijns5040041"},{"key":"e_1_2_25_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.11.002"},{"key":"e_1_2_25_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190428"},{"key":"e_1_2_25_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.06.042"},{"key":"e_1_2_25_40_1","first-page":"1","article-title":"Newborn screening for spinal muscular atrophy: Ontario testing & follow\u2010up recommendations","volume":"48","author":"McMillan HJ","year":"2020","journal-title":"Can J Neurol Sci."},{"key":"e_1_2_25_41_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180304"},{"key":"e_1_2_25_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2020.07.001"},{"key":"e_1_2_25_43_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190468"},{"key":"e_1_2_25_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"key":"e_1_2_25_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0831-9"},{"key":"e_1_2_25_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00415-w"},{"key":"e_1_2_25_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.11.054"},{"key":"e_1_2_25_48_1","unstructured":"MercuriE BaranelloG ServaisL et al.Onasemnogene abeparvovoec gene therapy for spinal muscular atrophy type 1: phase III study update (STR1VE\u2010EU). Virtual poster session. Presented at the 2020 International Annual Congress of the World Muscle Society; September 28\u2013October 2 2020."},{"key":"e_1_2_25_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05107-11"},{"key":"e_1_2_25_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.109"},{"key":"e_1_2_25_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00336-0"},{"key":"e_1_2_25_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2010.11.003"},{"key":"e_1_2_25_53_1","unstructured":"DayJW FinkelRS MercuriE et al.Adeno\u2010associated virus serotype 9 antibodies in patients with spinal muscular atrophy screened for treatment with gene\u2010replacement therapy onasemnogene abeparvovec\u2010xioi or AVXS\u2010101 IT. Presented at the 48th Annual Meeting of the Child Neurology Society October 23\u201026 2019 Charlotte NC."},{"key":"e_1_2_25_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.014"},{"key":"e_1_2_25_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1979.02130120032005"},{"key":"e_1_2_25_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2012.10.002"},{"key":"e_1_2_25_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/0890334410395761"},{"issue":"2","key":"e_1_2_25_58_1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jpeds.2009.11.014","article-title":"The mucosal immune system and its integration with the mammary glands","volume":"156","author":"Brandtzaeg P","year":"2020","journal-title":"J Pediatr."},{"key":"e_1_2_25_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62704-4"},{"key":"e_1_2_25_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50855"},{"key":"e_1_2_25_61_1","unstructured":"American College of Clinical Pharmacy. Reference values for common laboratory tests. Pediatric Self\u2010Assessment Program (PedSAP).https:\/\/www.accp.com\/store\/product.aspx?pc=pdsap_2019-2021. Accessed October 12 2020."},{"key":"e_1_2_25_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_2_25_63_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj\/051291"},{"key":"e_1_2_25_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0613-5"},{"key":"e_1_2_25_65_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-160177"},{"key":"e_1_2_25_66_1","unstructured":"Euopean Medicines Agency. Committee for Medicinal Products for Human Use and Committee for Advanced Therapies. Assessment report: Zolgensma. Updated March 26 2020.https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zolgensma-epar-public-assessment-report_en.pdf. Accessed March 5 2021."},{"key":"e_1_2_25_67_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2018.299156"},{"key":"e_1_2_25_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2006.02.018"},{"key":"e_1_2_25_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.070"},{"key":"e_1_2_25_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2008.00950.x"},{"key":"e_1_2_25_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.386"},{"key":"e_1_2_25_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2021.01.012"},{"key":"e_1_2_25_73_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0729"},{"key":"e_1_2_25_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.05.044"},{"key":"e_1_2_25_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13273"},{"key":"e_1_2_25_76_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1739831"},{"key":"e_1_2_25_77_1","unstructured":"ChandDH FinkelRS MercuriE et al.Intravenous onasemnogene abeparvovec for spinal muscular atrophy: cumulative safety report. Virtual presentation at the Cure SMA Annual Conference June 8\u201012 2020."},{"issue":"15","key":"e_1_2_25_78_1","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1212\/WNL.94.15_supplement.5483","article-title":"Thrombotic microangiopathy (TMA): a potential adverse reaction post Zolgensma (onasemnogene abeparvovec\u2010xioi) therapy for spinal muscular atrophy (SMA) (5483)","volume":"94","author":"Prabhu N","year":"2020","journal-title":"Neurology."},{"key":"e_1_2_25_79_1","unstructured":"Department of Health and Human Services National Institutes of Health.NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines). Bethesda MD: NIH Office of Science Policy; April 2019."},{"key":"e_1_2_25_80_1","unstructured":"US Centers for Disease Control and Prevention.National Institutes of Health.Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Atlanta GA: CDC; June 2020."},{"key":"e_1_2_25_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2020.03.002"},{"key":"e_1_2_25_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1725469"},{"key":"e_1_2_25_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"e_1_2_25_84_1","unstructured":"Medical Device EvaluationDivision. Pharmaceutical Safety and Environmental Health Bureau. Ministry of Health Labour and Welfare. Report on the deliberation results.https:\/\/www.pmda.go.jp\/files\/000237139.pdf. Accessed November 2 2020."},{"key":"e_1_2_25_85_1","unstructured":"European Medicines Agency. Annex I: Summary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/zolgensma\u2010epar\u2010product\u2010information_en.pdf. Accessed November 2 2020."},{"key":"e_1_2_25_86_1","unstructured":"Zolgensma (onasemnogeno abeparvoveque) Package insert. AveXis Inc 2020.https:\/\/portal.novartis.com.br\/upload\/imgconteudos\/4111.pdf. Accessed November 25 2020."},{"key":"e_1_2_25_87_1","unstructured":"Australian Product Information\u2014Zolgensma\u00ae (onasemnogene abeparvovec) for single\u2010dose intravenous infusion only.https:\/\/www.novartis.com.au\/system\/files\/product-info\/zol240221i.pdf. Accessed March 18 2021."},{"key":"e_1_2_25_88_1","unstructured":"Product Monograph Including Patient Medical Information\u2014Zolgensma\u2122 (onasemnogene abeparvovec) solution for intravenous infusion 2\u2009\u00d7\u20091013vector genomes\/mL.https:\/\/www.ask.novartispharma.ca\/download.htm?res=zolgensma_scrip_e.pdf&resTitleId=1747. Accessed June 9 2021."}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.27363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:54:08Z","timestamp":1725332048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.27363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/mus.27363"],"URL":"https:\/\/doi.org\/10.1002\/mus.27363","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"2020-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}